Kenvue Inc., the Summit-based consumer health giant, is celebrating a major milestone for one of its flagship brands with a high-powered scientific collaboration.
To mark the 80th anniversary of Aveeno®, the brand has entered into a three-year research and education agreement with Mayo Clinic. The partnership aims to advance the science of skin health through a mix of preclinical and clinical trials, professional education, and new innovation strategies.
The announcement carries significant weight for the New Jersey life sciences sector. Kenvue, which established its global headquarters in Summit in April 2025, continues to leverage the state’s “Medicine Chest of the World” reputation to drive global R&D.
The relationship between Aveeno and Mayo Clinic actually dates back eight decades. It was Mayo Clinic physicians who first documented the medical benefits of colloidal oatmeal—the “hero ingredient” that Aveeno pioneered—in dermatological literature.
“We are constantly pushing for innovation, staying on the cutting edge of research and testing,” Dr. Caroline Tillett, chief scientific officer at Kenvue said. “We are thrilled at the opportunity to collaborate with Mayo Clinic’s multi-disciplinary physicians to enhance our understanding of skin health.”
The new three-year program will focus specifically on Triple Oat® technology. Researchers will investigate its effectiveness on “compromised skin”—conditions where the skin barrier is weakened due to chronic dermatoses, aging, or environmental factors.
Key Pillars of the Collaboration:
- Clinical Investigations: Validating the superiority of oat-based formulations in relieving itching and extreme dryness (xerosis).
- Professional Education: Training dermatologists and healthcare providers on the latest advancements in skin barrier science.
- Consumer Insights: Bridging the gap between lab-based dermatological research and the everyday needs of skincare consumers.
By anchoring this new research initiative in Summit, Kenvue reinforces New Jersey’s position as a hub for both consumer goods and cutting-edge clinical science.
